Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammation, Oncology, and Neurodegenerative Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for P2RX7 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | P2RX7 ECD-Fc Fusion Protein Extracellular domain (Met1-Val595), HEK293 expressed, High purity (>95%), Endotoxin <1EU/µg, Sequence Verified |
View P2RX7 Products |
| Gene Delivery | P2RX7 Premade Lentivirus Particles Full-length ORF with native glycosylation sites for stable ion channel expression in HEK293 or CHO cells |
View P2RX7 Products |
| Benchmark Ab | Anti-P2RX7 (Reference Clone) Recombinant positive control for flow cytometry and binding assays |
View P2RX7 Products |
| Validator | P2RX7 siRNA Set Validated knockdown sequences for specificity confirmation in calcium flux assays |
View P2RX7 Products |
| Related Target: NLRP3 | NLRP3 Inflammasome Component Downstream signaling partner; essential for P2RX7-mediated IL-1β release pathway studies |
View NLRP3 Products |
| Related Target: IL1B | IL1B Effector cytokine released upon P2RX7/NLRP3 activation |
View IL1B Products |
| Related Target: P2RX4 | P2X4 Receptor Closest family member for selectivity screening; ATP-gated ion channel with overlapping expression profiles |
View P2RX4 Products |
| Related Target: CD39 | ENTPD1 (CD39) ATP-hydrolyzing enzyme regulating extracellular ATP levels and P2RX7 activation threshold |
View CD39 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Functional Ion Channel Expression & Complex Membrane Conformation | Premade Lentivirus particles for stable cell line generation (HEK293/CHO expressed); preserves native conformation for electrophysiology and calcium flux |
| P2X Family Selectivity (including P2X4, P2X1, P2X3) | Sequence-verified homolog panels strictly verified by mass spec; purified ECDs for off-target binding assays |
| Species Cross-Reactivity (Cyno/Mouse/Rat) | Human/Mouse/Rat/Cyno ortholog proteins available with >95% purity; sequence alignment verified for epitope conservation |
| Lack of Assay Controls | Sequence-verified Benchmark Antibodies and siRNA validators included for assay standardization |
| False Positives | Validated siRNA included for specificity checks |
Live P2RX7 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The P2RX7 therapeutic landscape is rapidly evolving. Major players like Lundbeck, J&J, Shionogi, Janssen, AstraZeneca, and GSK are intensifying the race for next-generation therapeutics, shifting focus from traditional monoclonal antibodies to CNS-penetrant small molecules and allosteric modulators. The current pipeline targets inflammatory disorders (rheumatoid arthritis, inflammatory bowel disease) and neurodegenerative conditions (Alzheimer's, Parkinson's, multiple sclerosis), driven by the receptor's role in NLRP3 inflammasome activation and IL-1β release. First-generation inhibitors face bioavailability and selectivity challenges, leading to strategies such as brain-penetrant compounds and peripheral-restricted approaches. A key emerging focus is the non-functional P2X7 (nfP2X7) conformation specifically expressed in the tumor microenvironment, which is being targeted by biologics from companies like Biosceptre. The next wave is also targeting allosteric modulation (e.g., Evotec) and cell therapy enhancement (knockout in CAR-T cells).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Antagonist | Lundbeck, J&J, Shionogi, Janssen, AstraZeneca, GSK | Depression, CNS, Inflammation, Rheumatoid Arthritis, Pain | Cell-based Calcium Flux Assay using lentivirus-stable cells; Selectivity Panel vs P2RX4/P2RX1 using purified ECD proteins |
| Allosteric Modulator | Evotec, Ra Pharmaceuticals | Alzheimer's Disease | Conformation-specific binding assays; HEK293-expressed mutant proteins for allosteric site mapping |
| Monoclonal Antibodies (nfP2X7) | Biosceptre | Solid Tumors | Epitope Specificity Assay (Need Sequence-verified ECDs) |
| Biologic (mAb/ADC) | Emerging Biotechs | Solid Tumors (Immunotherapy) | Internalization assays using high-purity ECD-Fc; Cross-species reactivity for toxicology models |
| Nanobodies | Academic/Biotech Consortiums | Inflammatory Bowel Disease | High-concentration Binding (Need High-purity recombinant targets) |
| Cell Therapy Enhancer | Academic Consortia | CAR-T Persistence | P2RX7 knockout validation using siRNA and lentiviral systems |
Key Genetic Variants of P2RX7
P2RX7 has known mutations associated with disease and drug response. Key variants include:
- A somatic mutation found in a colorectal cancer sample (UniProt VAR_036444).
- dbSNP variant rs17525809 (UniProt VAR_057665).
- dbSNP variant rs28360445 (UniProt VAR_079880). These variants may affect receptor function, expression, or selectivity screening, and can be studied using TarMart's mutant protein and lentivirus tools.